Clinical endocrinology · 2026
Pre-Treatment With Potassium Iodide and Higher Radioiodine Dose Are the Risk Factors of Mid-to-Late-Phase Transient Thyrotoxicosis Following Radioiodine Therapy for Graves' Disease in Japanese Patients: A Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Matsuda Erika, Osaki Yoshinori, Maruo Kazushi, Fukazawa Hiroshi, Matsuda Takaaki, Nakajima Rikako, Murayama Yuki, Sugano Yoko, Iwasaki Hitoshi, Sekiya Motohiro, Shimano Hitoshi
Аннотация
BACKGROUND: Radioiodine therapy (RIT) is an effective treatment for Graves' disease (GD). However, some patients experience transient exacerbation of thyrotoxicosis in the mid-to-late-phase period (2 weeks to several months post-RIT), and its risk factors are poorly understood. This study aimed to investigate the clinical predictors of mid-to-late-phase transient exacerbation of thyrotoxicosis following RIT.
METHODS: We conducted a retrospective cohort study involving 200 Japanese patients with GD who received RIT at a single university hospital. Patients were categorized according to the clinical course as follows: no exacerbation, transient exacerbation or persistent exacerbation, likely due to residual or worsening GD. An exacerbation was defined as an increase of ≥ 1.0 pg/mL in free triiodothyronine (FT3) or ≥ 1.0 ng/dL in free thyroxine. Multivariable logistic regression, guided by the Akaike Information Criterion, was used to identify risk factors.
RESULTS: Transient thyrotoxicosis was observed in 62 patients (31.0%). Multivariate logistic regression identified a higher 131I dose as a significant independent risk factor (odds ratio [OR] = 1.338, 95% confidence interval [CI] = 1.048-1.710, p = 0.020). Although not statistically significant, high pre-RIT FT3 levels and potassium iodide (KI) administration were identified as relevant predictors in the model.
CONCLUSIONS: A higher 131I dose was an independent risk factor for mid-to-late-phase transient thyrotoxicosis after RIT. Higher pre-RIT FT3 levels and KI use may contribute to this risk. Identifying patients with these factors may be helpful for closer post-RIT monitoring to prevent complications and avoid misdiagnosing this transient event as a treatment failure.
METHODS: We conducted a retrospective cohort study involving 200 Japanese patients with GD who received RIT at a single university hospital. Patients were categorized according to the clinical course as follows: no exacerbation, transient exacerbation or persistent exacerbation, likely due to residual or worsening GD. An exacerbation was defined as an increase of ≥ 1.0 pg/mL in free triiodothyronine (FT3) or ≥ 1.0 ng/dL in free thyroxine. Multivariable logistic regression, guided by the Akaike Information Criterion, was used to identify risk factors.
RESULTS: Transient thyrotoxicosis was observed in 62 patients (31.0%). Multivariate logistic regression identified a higher 131I dose as a significant independent risk factor (odds ratio [OR] = 1.338, 95% confidence interval [CI] = 1.048-1.710, p = 0.020). Although not statistically significant, high pre-RIT FT3 levels and potassium iodide (KI) administration were identified as relevant predictors in the model.
CONCLUSIONS: A higher 131I dose was an independent risk factor for mid-to-late-phase transient thyrotoxicosis after RIT. Higher pre-RIT FT3 levels and KI use may contribute to this risk. Identifying patients with these factors may be helpful for closer post-RIT monitoring to prevent complications and avoid misdiagnosing this transient event as a treatment failure.